Papillary carcinoma of the thyroid; Papillary thyroid cancer; Papillary thyroid carcinoma
Papillary carcinoma of the thyroid is the most common cancer of the thyroid gland. The thyroid gland is located inside the front of the lower neck.
About 85% of all thyroid cancers diagnosed in the United States are the papillary carcinoma type. It is more common in women than in men. It may occur in childhood, but is most often seen in adults between ages 20 and 60.
The cause of this cancer is not known. A genetic defect or family history of the disease may be a risk factor.
Radiation increases the risk of developing thyroid cancer. Exposure may occur from:
Radiation given through a vein (through an IV) during medical tests and treatments does not increase the risk of developing thyroid cancer.
Thyroid cancer often begins as a small lump (nodule) in the thyroid gland.
While some small lumps may be cancer, most (90%) thyroid nodules are harmless and are not cancerous.
Most of the time, there are no other symptoms.
If you have a lump on your thyroid, your health care provider may order the following exams:
Genetic testing may be done on the biopsy sample to see what genetic changes (mutations) may be present. Knowing this may help guide treatment recommendations.
Thyroid function tests are often normal in people with thyroid cancer.
Thyroid cancer treatment may include:
Surgery is done to remove as much of the cancer as possible. The bigger the lump, the more of the thyroid gland must be removed. Often, the entire gland is taken out.
After the surgery, you may receive radioiodine therapy, which is often taken by mouth. This substance kills any remaining thyroid tissue. It also helps make medical images clearer, so doctors can see if there is any cancer left behind or if it comes back later.
Further management of your cancer will depend on many factors such as:
If surgery is not an option, external radiation therapy can be useful.
After surgery or radioiodine therapy, you will need to take medicine called levothyroxine for the rest of your life. This replaces the hormone the thyroid would normally make.
Your provider will likely have you take a blood test every several months to check thyroid hormone levels. Other follow-up tests that may be done after treatment for thyroid cancer include:
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you not feel alone.
The survival rate for papillary thyroid cancer is excellent. More than 90% of adults with this cancer survive at least 10 to 20 years. The prognosis is better for people who are younger than 40 and for those with smaller tumors.
The following factors may decrease the survival rate:
Call your provider if you have a lump in your neck.
Haddad RI, Nasr C, Bischoff L. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018;16(12):1429-1440. PMID: 30545990 pubmed.ncbi.nlm.nih.gov/30545990/.
Haugen BR, Alexander Erik K, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. PMID: 26462967 pubmed.ncbi.nlm.nih.gov/26462967/.
Kwon D, Lee S. Invasive thyroid cancer. In: Myers EN, Snyderman CH, eds. Operative Otolaryngology Head and Neck Surgery. 3rd ed. Philadelphia, PA: Elsevier; 2018:chap 82.
National Cancer Institute website. Thyroid cancer treatment (adult) (PDQ) - health provisional version. www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional. Updated January 30, 2020. Accessed February 1, 2020.
Thompson LDR. Malignant neoplasms of the thyroid gland. In: Thompson LDR, Bishop JA, eds. Head and Neck Pathology. 3rd ed. Philadelphia, PA: Elsevier; 2019:chap 25.
Tuttle RM and Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019;104(9):4087-4100. PMID: 30874735 pubmed.ncbi.nlm.nih.gov/30874735/.BACK TO TOP
Review Date: 1/21/2020
Reviewed By: Robert Hurd, MD, Professor of Endocrinology and Health Care Ethics, Xavier University, Cincinnati, OH. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.